|View printer-friendly version|
|BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California|
HACKENSACK, N.J. and PETACH TIKVAH, Israel,
"NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains"
"Modulation of CSF miRNAs in ALS phase 2 study participants treated with MSC-NTF cells (NurOwn®)"
"Our Phase 2 placebo-controlled trial demonstrated promising clinical activity for NurOwn® in ALS, and the subgroup analyses confirm that ALSFRS-R subdomains contribute to this treatment effect. The CSF biomarker data confirms that micro-RNA released by NurOwn® may contribute to its therapeutic effect in ALS", said
"We are pleased to have these scientific abstracts accepted at the prestigious AAN Annual Meeting, which is the largest North American Neurology conference. We are committed to continuing to understand the value that NurOwn brings to ALS through innovative clinical and scientific evaluation, and to advance the phase 3 pivotal study to bring a meaningful solution to ALS patients," commented BrainStorm's CEO
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorms-nurown-phase-2-als-clinical-trial-and-biomarker-abstracts-accepted-for-platform-presentations-at-the-70th-annual-american-academy-of-neurology-meeting-in-los-angeles-california-300594936.html